AI assistant
SYNLOGIC, INC. — Director's Dealing 2023
Nov 15, 2023
35028_dirs_2023-11-14_1239dcf5-e824-4ce6-9722-5df26622dff8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SYNLOGIC, INC. (SYBX)
CIK: 0001527599
Period of Report: 2023-11-10
Reporting Person: JENSEN MICHAEL VANGSTED (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-11-10 | Stock Option (right to buy) | $33.45 | D | 15332 | Disposed | 2032-03-03 | Common Stock (15332) | Direct |
| 2023-11-10 | Stock Option (right to buy) | $9.30 | D | 13332 | Disposed | 2033-03-16 | Common Stock (13332) | Direct |
| 2023-11-10 | Stock Option (right to buy) | $9.30 | D | 6666 | Disposed | 2033-03-16 | Common Stock (6666) | Direct |
| 2023-11-10 | Stock Option (right to buy) | $1.85 | A | 15332 | Acquired | 2032-03-03 | Common Stock (15332) | Direct |
| 2023-11-10 | Stock Option (right to buy) | $1.85 | A | 13332 | Acquired | 2033-03-16 | Common Stock (13332) | Direct |
| 2023-11-10 | Stock Option (right to buy) | $1.85 | A | 6666 | Acquired | 2033-03-16 | Common Stock (6666) | Direct |
Footnotes
F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
F2: These stock options vested 25% on the first anniversary of the March 3, 2022 grant date, and vest in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F3: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
F4: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.